Thursday, June 24, 2010

Presage Biosciences Ups Funding To $3.8M

Seattle-based Presage Biosciences, the spinout of the Fred Hutchinson Cancer Research Center, has upped its total funding to $3.8M, up from the $3.1M the firm announced in March. The additional funding was revealed through a regulatory filing by the firm earlier this week, and also indicates the total targeted amount to be raised in this round is now $4.0M. Presage is developing technology which helps improve the cancer drug discovery process. The firm was founded and is headed by Thane Kreiner. More information »